South Korea PCSK9-Targeted Therapy Market Size, Share, Growth, and Industry Analysis, By Drug Type / Modality (Monoclonal Antibodies (mAbs) Alirocumab Evolocumab, siRNA-based Therapies Inclisiran, Gene Editing and Other Novel Modalities CRISPR-based approaches Antisense oligonucleotides (ASOs) ), By Indication  (Heterozygous Familial Hypercholesterolemia (HeFH), Atherosclerotic Cardiovascular Disease (ASCVD), Homozygous Familial Hypercholesterolemia (HoFH), Hyperlipidemia (Non-FH) ) and Forecast, 2026-2034

South Korea PCSK9-Targeted Therapy Market Trends

Longer-acting and gene-directed treatment platforms reshape lipid management

Treatment development is moving from repeated antibody injections toward infrequent RNA-silencing and potentially one-time gene-editing interventions. Inclisiran is already subject to Korean post-marketing surveillance for primary hypercholesterolemia and mixed dyslipidemia. Meanwhile, VERVE-102 Phase 1b data from 35 participants showed PCSK9 reductions of 51%–88% and LDL-C reductions reaching 62%, sustained for follow-up extending to 18 months.

Technology diversification is also extending toward oral administration. Merck's investigational once-daily enlicitide reduced LDL-C by 59.4% versus placebo at week 24 in Phase 3 HeFH testing, while adherence exceeded 97% in another pivotal Phase 3 program. These developments could shift treatment from injectable specialty-care pathways toward broader chronic lipid management. South Korea's underlying treatment opportunity remains substantial because dyslipidemia prevalence reaches 87.0% among adults with diabetes, 72.4% among those with hypertension and 55.2% among adults with obesity.

South Korea PCSK9-Targeted Therapy Market Drivers

Expanding high-risk lipid population supports South Korea PCSK9-Targeted Therapy Market Growth

South Korea's rising hypercholesterolemia burden strengthens demand for potent LDL-lowering therapies beyond conventional statins. Age-adjusted hypercholesterolemia prevalence increased from 8.8% in 2007 to 22.4% in 2022, while crude prevalence reached 27.4%. Awareness reached 68.0%, treatment 61.2%, and overall control 54.1%; among treated patients, 87.4% achieved cholesterol targets. The remaining uncontrolled high-risk population, together with FH and established cardiovascular disease cohorts, supports additional use of PCSK9-directed treatment.

South Korea PCSK9-Targeted Therapy Market Restraints

Premium biologic economics and treatment escalation requirements limit broad uptake

PCSK9 therapies compete against established generic statins, ezetimibe and combination regimens, making reimbursement positioning and patient selection critical. Although 61.2% of South Koreans with hypercholesterolemia receive treatment and 87.4% of medicated patients achieve target cholesterol levels, the remaining population requiring escalation is narrower than total disease prevalence suggests. This creates payer pressure to prioritize severe FH, recurrent cardiovascular disease and persistently uncontrolled LDL-C populations rather than the entire 27.4% crude hypercholesterolemia population.

South Korea PCSK9-Targeted Therapy Market Opportunities

Oral inhibition, RNA silencing and one-time editing broaden therapeutic possibilities

Next-generation platforms can address adherence and injection-frequency barriers. Enlicitide produced a 55.8% primary-analysis LDL-C reduction at week 24 and maintained statistically significant lowering through 52 weeks, with study-intervention adherence of 97%. VERVE-102 achieved up to 88% PCSK9 lowering and 62% LDL-C lowering after a single infusion, with durability observed for up to 18 months. Such profiles create opportunities for differentiated chronic, infrequent-dose and potentially one-time treatment models.

Challenges in South Korea PCSK9-Targeted Therapy Market

Long-term safety evidence and access economics remain critical barriers

Permanent gene editing raises a different evidence threshold from reversible antibodies or siRNA. VERVE-102's published 2026 dataset involved 35 participants, with doses ranging from 0.3 mg/kg to 1.0 mg/kg and follow-up extending to 18 months, leaving larger and longer studies necessary before broad clinical adoption. Simultaneously, oral PCSK9 development must translate Phase 3 LDL reductions of approximately 56%–59% into cardiovascular outcomes, regulatory approval and economically viable reimbursement.

South Korea PCSK9-Targeted Therapy Market Segmentation

The industry is segmented by drug type/modality, indication, route, distribution channel and patient type. In modality terms, monoclonal antibodies lead with approximately 50.3% of 2026 value, followed by siRNA at 33.7% and novel modalities at 16.0%. By indication, HeFH represents approximately 48.7% of the supplied 2026 total.

By Drug Type / Modality

Monoclonal antibodies, including alirocumab and evolocumab, constitute the largest modality, rising from USD 96.18 million in 2025 to USD 107.22 million in 2026 and USD 255.77 million by 2034, representing an 11.48% CAGR.

Within the remaining modalities, siRNA-based therapies centered on inclisiran advance from USD 71.87 million in 2026 to USD 167.07 million in 2034 at 11.12% CAGR. Gene editing and other novel modalities, including CRISPR approaches and ASOs, record the faster 11.21% CAGR, reaching USD 79.96 million by 2034.

By Indication

HeFH is the largest indication, valued at USD 103.94 million in 2026 and forecast to reach USD 248.13 million by 2034, expanding at 11.49% CAGR. It contributes about 48.7% of the 2026 indication total.

ASCVD is the fastest-growing supplied indication at 11.72% CAGR, increasing from USD 53.70 million in 2026 to USD 130.33 million in 2034. HoFH and non-FH hyperlipidemia each expand at 10.94% CAGR.

By Route of Administration

Subcutaneous injection remains the principal commercial route because marketed mAbs and inclisiran use injectable delivery, while intravenous administration is strategically relevant to experimental gene-editing platforms. Current development spans repeated antibody dosing, infrequent siRNA administration and single-infusion concepts producing up to 62% LDL-C reduction in early clinical testing.

Oral therapy remains pipeline-led rather than an established commercial category. Phase 3 enlicitide data demonstrated 59.4% LDL-C reduction at week 24, highlighting the potential for oral delivery to broaden future treatment accessibility. No separate route-level revenue or CAGR figures were supplied.

By Distribution Channel

Hospital pharmacies are positioned strongly because PCSK9 therapies frequently serve specialist-managed FH and secondary-prevention patients. With hypercholesterolemia awareness at 68.0% and treatment at 61.2%, specialist identification and prescribing remain important components of the patient pathway.

Retail and online pharmacies could gain relevance if oral PCSK9 products secure approval, while injectable products retain more structured clinical dispensing pathways. Phase 3 oral adherence of at least 97% indicates the potential convenience advantage of pharmacy-based chronic dispensing. No channel-specific CAGR was provided.

By Patient Type

Secondary-prevention patients with established ASCVD represent a clinically important group because intensive LDL reduction is prioritized after cardiovascular events. The broader Korean risk environment includes dyslipidemia prevalence of 72.4% among adults with hypertension and 87.0% among adults with diabetes.

Primary-prevention high-risk and statin-intolerant populations provide additional addressable cohorts. Oral PCSK9 Phase 3 studies have specifically included patients receiving moderate/high-intensity statins or having documented statin intolerance, with LDL reductions exceeding 55% at 24 weeks.

South Korea PCSK9-Targeted Therapy Market Counties Outlook

South Korea constitutes the complete geographic scope of the supplied dataset. National modality value totals USD 213.26 million in 2026, compared with USD 191.59 million in 2025, and is forecast at USD 502.80 million by 2034, an 11.27% CAGR. Monoclonal antibodies contribute approximately 50.3%, siRNA therapies 33.7%, and novel modalities 16.0% in 2026.

No Seoul, Busan, Incheon, Gyeonggi, Daegu or other provincial/county revenue allocation was supplied; therefore, county-level percentage shares are not fabricated. National indication data show HeFH at USD 103.94 million, ASCVD at USD 53.70 million, HoFH at USD 33.20 million and non-FH hyperlipidemia at USD 22.60 million in 2026. South Korea's biologics infrastructure is substantial; Samsung Biologics reported manufacturing capacity reaching 784,000 liters after Plant 5 entered operation, illustrating the country's broader large-scale biopharmaceutical production ecosystem.

Top players in South Korea PCSK9-Targeted Therapy Market

1. Amgen Inc.
2. Novartis AG
3. Sanofi S.A.
4. Regeneron Pharmaceuticals, Inc.
5. Merck & Co., Inc.
6. Eli Lilly and Company
7. LIB Therapeutics
8. AstraZeneca PLC
9. Silence Therapeutics plc
10. Arrowhead Pharmaceuticals, Inc.
11. Alnylam Pharmaceuticals, Inc.
12. Ionis Pharmaceuticals, Inc.

South Korea PCSK9-Targeted Therapy Market Share: Leading Company Positioning

• Amgen Inc.— Amgen occupies a leading commercial position through evolocumab, an established monoclonal-antibody PCSK9 inhibitor serving high-risk hypercholesterolemia and ASCVD populations. Commercial mAbs collectively account for approximately50.3%of the supplied 2026 modality value. Amgen benefits from physician familiarity with antibody-based LDL lowering, specialist prescribing infrastructure and the established role of PCSK9 inhibition after insufficient response to conventional lipid therapy. Exact company-level percentage revenue was not supplied and is therefore not estimated.
• Novartis AG— Novartis is positioned around inclisiran, differentiating through RNA interference and infrequent maintenance dosing rather than conventional antibody administration. South Korea's siRNA category accounts for approximately33.7%of supplied 2026 modality value. Leqvio is also covered by mandatory Korean regulatory post-marketing surveillance assessing effectiveness and safety in primary hypercholesterolemia and mixed dyslipidemia, reinforcing its established regulatory presence. Exact company-level percentage revenue was not provided.

Recent Developments in South Korea PCSK9-Targeted Therapy Market

• 2026: Eli Lilly reported Phase 1b VERVE-102 results in 35 patients, showing PCSK9 reductions up to 88% and LDL-C reductions up to 62%, with effects observed for as long as 18 months.
• 2025: Merck reported Phase 3 CORALreef HeFH results for oral enlicitide, demonstrating a 59.4% LDL-C reduction at week 24 versus placebo.
• 2025: CORALreef Lipids showed a 55.8% primary-analysis LDL-C reduction, sustained effects through 52 weeks, and approximately 97% treatment adherence.
• 2025: Korean regulatory post-marketing surveillance of Novartis' Leqvio continued for approved primary hypercholesterolemia and mixed dyslipidemia indications.
• 2025: Eli Lilly announced the acquisition of Verve Therapeutics for approximately USD 1.3 billion, strengthening its position in one-time PCSK9 gene-editing development.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year, historical assessment covering 2022–2024, and forecasts through 2034. Supplied mandatory numerical tables were treated as the primary source for revenue, segment contribution and CAGR calculations. Modality totals of USD 191.59 million in 2025, USD 213.26 million in 2026 and USD 502.80 million in 2034 anchor the headline forecast. Secondary evidence was used only for clinical, epidemiological, technology, manufacturing and company context. Percentage contributions were mathematically derived from supplied totals, while unsupported county, company, route, channel and patient-type revenue shares were intentionally not fabricated.